Carisma Therapeutics Inc.
CARM Healthcare Biotechnology
Carisma Therapeutics Inc.’s revenue for fiscal 2024 (year ended December 2024) was $19.6 million, up 31.6% from fiscal 2023. In the quarter to September 2025, revenue grew 392.0%, EPS grew 445.2% and free cash flow grew 114.7%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
Follow CARM
Carisma Therapeutics Inc. (CARM) Piotroski F-score
Carisma Therapeutics Inc.'s Piotroski F-score for fiscal 2024 is 4 out of 9: 4 of nine tests of profitability, leverage and efficiency passed, unchanged from fiscal 2023.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2024 | 4 | 0.00 |
| FY2023 | 4 | 2.00 |
| FY2022 | 2 | 0.00 |
| FY2017 | 2 | (5.00) |
| FY2016 | 7 | — |
How fiscal 2024’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (100.78%) | (107.45%) | Fail | 0 |
| Positive operating cash flow | (59.92m) | (81.18m) | Fail | 0 |
| Rising return on assets | (100.78%) | (107.45%) | Pass | 1 |
| Cash flow above net income | 560.00k | 5.70m | Pass | 1 |
| Falling long-term leverage | 0.00 | 0.00 | Pass | 1 |
| Rising current ratio | 1.48 | 5.06 | Fail | 0 |
| No new shares issued | 41,456,200 | 33,524,200 | Fail | 0 |
| Rising gross margin | 100.00% | 100.00% | Fail | 0 |
| Rising asset turnover | 0.33 | 0.18 | Pass | 1 |
| Piotroski F-score | Mixed | 4 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| CARM Carisma Therapeutics Inc. | 4 |
| MLEC Moolec Science SA compare | 3 |
| ITRMF Iterum Therapeutics PLC compare | 2 |
| NEXI NexImmune, Inc. compare | — |
| PTIX Atrinsic Inc. compare | — |
| GNPX GENPREX compare | — |
| ARTL Artelo Biosciences, Inc. compare | — |
| ABPO Abpro Holdings Inc. compare | — |
| TRVN Trevena, Inc. compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover